GVHD is a common complication in patients after allo-SCT. Early detection is important because early therapy may improve the outcome. We evaluated contrastenhanced ultrasound (CEUS) in patients with GVHD to assess typical imaging features. CEUS was performed in nine patients with histologically proven GVHD. As a control four healthy volunteers and six patients with Crohn's disease (CD) were examined. We employed a high-resolution multi-frequency transducer (6-9 MHz) with contrast harmonic imaging. After the injection of 2.4 mL SonoVue (Bracco, Milan, Italy) intravenously data were acquired and stored digitally. Regions of interest were manually placed over the surrounding mesenteric fat, bowel wall and bowel lumen. Maximum signal increase of each compartment was calculated. Patients with CD and GVHD showed significant contrast uptake in the bowel wall. In contrast to CD patients and healthy volunteers, patients with GVHD showed transmural penetration of microbubbles into the bowel lumen. We assume that the damaged gut mucosal barrier in GVHD enables the microbubbles to penetrate through the bowel wall into the bowel lumen. The penetration of microbubbles into the bowel lumen may serve as a novel diagnostic feature for GVHD if confirmed in controlled clinical trials.
Introduction
Allogeneic PBSCT is a well-established treatment modality for a variety of nonmalignant and malignant disorders. Acute GVHD is a major complication after allo-SCT, and can cause severe damage to skin, liver and intestine, resulting in high morbidity and mortality rates. Approximately 50-70% of patients who have received an allogeneic transplant develop GVHD. 1 Intestinal GVHD is a progressive process that can affect all sections of the alimentary tract. The terminal ileum and the colon are predominant sites. Symptoms are non-specific and may include anorexia, nausea, vomiting, watery diarrhea, intestinal bleeding, abdominal pain and ileus. The differential diagnoses include drug-related symptoms, acute toxicity secondary to conditioning, and acute intestinal infection by CMV, other viruses and Clostridium difficile. The standard for diagnosis and staging of intestinal GVHD is the combination of clinical symptoms and histological analysis of the samples obtained by endoscopy. Mucosal edema, defects of the basal membrane, apoptosis of enterocytes, destroyed crypt morphology, erosions, and ulceration characterize the histological findings in acute GVHD. 2 Early detection of intestinal GVHD is of paramount interest, because early therapeutic intervention may prevent progression to higher-grade disease, and therefore improve patient outcome. Patients requiring more than one line of treatment for GVHD have an extremely poor prognosis. 3 It may be difficult and risky to perform a diagnostic endoscopy with biopsies in patients who are in poor clinical condition and at high risk of bleeding due to a low platelet count. Therefore, an early noninvasive diagnostic tool is desirable.
In our ongoing effort to detect and assess intestinal GVHD at an early stage, we performed contrast-enhanced ultrasound (CEUS) in patients with known GVHD to assess typical changes within their bowel wall based on our recent experience derived from patients with inflammatory bowel disease. 4 To our knowledge there are no published studies evaluating patients with GVHD with CEUS. The purpose of our study was to detect and assess typical morphological and bowel wall features in patients with GVHD using highresolution linear CEUS.
Patients and methods

Patients
A total of nine patients presenting with clinical symptoms of intestinal GVHD were included. They had received allo-SCT with PBSCs from HLA-identical siblings (n ¼ 2) or matched unrelated donors (n ¼ 7). Details of patient characteristics are given in Table 1 .
Five patients suffered from classical acute GVHD, three patients had delayed acute GVHD after tapering of immunosuppression or treatment with donor lymphocyte infusions, and one patient presented with diarrhea and abdominal cramps in the course of severe sclerodermatous chronic GVHD. Clinical acute GVHD was graded according to Prezpiorka et al., 5 chronic GVHD was assessed as suggested by the National Institutes of Health consensus conference. 6 Clinically suspected GVHD was confirmed by endoscopy and histological examination in seven patients. In two patients endoscopy could not be performed due to their poor clinical condition, but both had additional skin manifestations of GVHD. Viral specimens from stool samples and biopsies were assessed in all patients, and none suffered from clinically relevant viral superinfection. All patients had been previously treated with or were taking calcineurin inhibitors and receiving high-dose steroids. Seven patients were treated with additional immunosuppressive drugs. Details of GVHD and outcome are given in Table 2 .
The patients with GVHD were examined with CEUS as a clinical routine examination. Time from onset of intestinal symptoms until CEUS varied between 1 and 7 days (median 3 days). Informed consent of all patients was obtained for the examination. The internal review board gave consent to publish the acquired data.
As a reference group we examined four healthy volunteers (two females, two males, age range 30-44 years, median 32 years) without any known diseases. Additionally, we evaluated the data from six patients with histologically proven Crohn's disease (CD), who had had an acute episode (CD activity index4200); these were assessed for inflammation (four female, two male, age range 28-39 years, median 32 years). We therefore had a control group with no known bowel disease as well as a control group with known chronic inflammatory bowel disease.
Ultrasound
An examiner experienced in ultrasound (15 years experience, more than 50 000 documented examinations) performed all examinations. To localize affected bowel loops, the abdomen was first scanned applying a convex multifrequency sector transducer (2-4 MHz, LOGIQ 9, GE, Milwaukee, WI, USA) by a sweep technique using B-scans. A standard search pattern was used by first identifying the cecum and terminal ileum, followed by colonic assessment starting at the cecum and scanning toward the sigmoid colon. Bowel loops showing a wall edema with wall thickness of more than 4 mm were further investigated employing a high-resolution linear multi-frequency transducer (6-9 MHz, LOGIQ 9, GE). For vessel and perfusion assessment, color-coded Doppler sonography and power Doppler examination were performed. For CEUS imaging we used a second generation blood pool contrast medium (SonoVue) intravenously. SonoVue is an ultrasound contrast medium which consists of gas bubbles containing sulphur-hexafluoride. 7 The bubbles have a mean diameter of 2.5 mm while more than 90% of the bubbles are smaller than 8 mm. The cover of these nontoxic gas bubbles consists of a phospholipid monolayer, which stabilizes the gas bubble. The injected dispersion contains 500 million microbubbles per milliliter, holding 8 mL gas (sulphur-hexafluoride) per milliliter.
After identifying an affected bowel loop the linear multifrequency transducer was oriented perpendicular to the bowel wall for an optimal transversal depiction of the bowel loop, using B-scan imaging with pulse inversion technique 8 and contrast harmonic imaging. 9 We then injected 2.4 mL SonoVue in a peripheral antecubital vein followed by a 10 mL saline flush. For CEUS scanning, we used the low-MI (mechanical Index) technique (MI o0.2) to preserve microbubble integrity. The conventional B-scan as well as the contrast-enhanced scan, which was displayed with an integrated subtraction algorithm, was depicted and digitally recorded simultaneously (true agent detection mode). Data acquisition was started immediately after the bolus injection, for 100 s. All data were stored digitally for further evaluation. A time-intensity curve (TIC) analysis was performed based on the raw digital data. Circular-shaped regions of interest (ROI) with a diameter of 5 mm were located within the bowel lumen, the bowel wall and the surrounding mesenteric fat. To compensate for motion artifacts of the bowel during data acquisition all ROIs were adapted manually along the scanning time for further evaluation.
As the healthy volunteers showed no bowel wall thickening, we identified the terminal ileum in these subjects to achieve a standardized anatomical region. Analogous to the procedure described above, we positioned our ROIs in the surrounding mesenteric fat, the bowel wall and the bowel lumen.
Data analysis
Numeric data of the three different time-intensity curves representing the signal of the bowel lumen, bowel wall and the surrounding fat tissue were exported to an Excel sheet (Office: mac 2008, version 12.2.3; Microsoft, Redmond, WA, USA) for further graphical and statistical evaluation. Individual graphs of patients with known GVHD, CD and healthy volunteers were processed based on the acquired signal (dB) and the acquisition time (seconds after injection) with a time resolution of 0.25 s. Based on the signal intensities acquired between second 0 and second 1 after contrast injection a mean baseline signal was calculated to take the background signal into account. The maximum signal (dB) value of all data within the acquisition time during the 100 s period was evaluated. By subtracting the baseline signal from the maximum signal, the maximum signal increase of each compartment was calculated.
Results
Applying color-coded Doppler sonography and power Doppler a diffuse increased vascularization of the bowel wall was assessed in patients with CD and GVHD. Because of major blooming artifacts both techniques showed suboptimal results in patients with GVHD, mostly because of the fluid-filled bowels accompanied by hyperperistalsis, which hindered subtle evaluation of the bowel wall and lumen. Therefore, quantitative evaluation of the colorcoded Doppler sonography and power Doppler data was not feasible.
The CEUS examination was technically successful in all patients and healthy volunteers. There were no examination-related complications or side effects. The ultrasound examination performed by an experienced examiner took up to 30 min (median 22 min) procedure time. With a depth limitation of 8 cm while applying the high-resolution linear probe we did not experience any problems in imaging the bowel in all patients examined.
In healthy volunteers, the mean signal increase within the mesenteric fat was 2.59 dB with an increasing average bowel wall signal of 2.60 dB (Table 3) . Visually, there was no signal increase representing microbubbles within the bowel lumen. Calculating the ROIs within the bowel lumen, we assessed a slight mean signal increase of 0.28 dB, which was probably induced by probe motion artifacts resulting in a baseline signal of 0.23 dB in healthy volunteers.
In patients with known CD, we found a mean signal increase of 3.58 dB of the surrounding mesenteric fat, as well as a mean bowel wall signal increase of 8.96 dB. Visually, no microbubbles were detected by ultrasound within the bowel lumen, although we measured a minimal increased signal of 1.31 dB from a mean baseline signal of 0.12 dB. This signal was based on motion artifacts of residual stool within the bowel lumen.
In patients suffering from GVHD, there was an increased mean baseline signal of 3.54 dB in the surrounding mesenteric fat (Figure 1 ). This compartment showed a mean maximum signal increase of 5.27 dB, whereas the affected bowel wall had a maximum increase of 8.01 dB. In all patients with GVHD, the intravenously injected microbubbles were detected in the affected bowel lumen (Figure 2 ). Our visual impression was supported by a measured maximum signal increase of 7.88 dB (mean).
In six of nine patients with GVHD, we assessed the bowel wall thickening in the terminal ileum and cecum, whereas in three of nine patients the preterminal ileum represented the affected bowel.
Discussion
There are no published studies examining the application and assessment of CEUS in patients with GVHD.
In our feasibility study we detected penetration of intravenously applied ultrasound contrast medium through the bowel wall into the bowel lumen exclusively in patients with proven GVHD. These findings were first noticed visually and confirmed by quantitative analysis of the ultrasound signal. In this preliminary study, the penetration of the gas bubbles, which have a mean diameter of 2.5 mm, was not documented in the control groups, composed of patients suffering from chronic inflammatory bowel disease and completely healthy volunteers with no known bowel disease.
Considering the current literature regarding intestinal GVHD diagnosis, there are several manuscripts describing the typical appearance and features based on computed tomography (CT) imaging. In the most recent paper by Brodoefel et al., patients with early (n ¼ 20) and late (n ¼ 15) onset of GVHD are evaluated. 10 Nonspecific CT features such as bowel wall thickening (90 and 100%, respectively), abnormal bowel wall enhancement (90 and 87%, respectively) and excessive fluid filling (90 and 100%, respectively) were reported. Another prospectively performed study analyzes 42 consecutive patients with gastrointestinal complaints after allo-SCT. 11 GVHD was found in 62% of patients, followed by gastritis (19%), CMV enteritis (11%), bacterial enteritis (6%) and toxic mucosal damage (2%). CT findings included small bowel and colonic bowel wall thickening resulting in luminal narrowing in several patients, while the CT features were not helpful in discerning the different causes of the gastrointestinal symptoms. Magnetic resonance imaging-based studies currently consist only of case reports. 12, 13 Basically, magnetic resonance imaging findings are reported to be nearly identical to the known CT features. Figure 1 Mean maximum signal increase is calculated by subtracting the baseline signal (dB during the first second of examination) from the maximum signal during the first 100 s recorded after i.v. contrast agent (SonoVue) injection (y axis). One s.d. is marked by whiskers. Increased contrast uptake within the bowel wall, as well as in the surrounding fat, can be observed in patients with Crohn's disease and GVHD. Contrast medium within the bowel lumen is only visible in patients with GVHD.
Table 3
The baseline signal (dB) is calculated as a mean value during the first second of data acquisition after injection of the contrast media The maximum signal increase (dB) is calculated by subtracting the baseline signal from the maximum acquired ultrasound signal. The reference group consists of healthy volunteers (healthy 1-4) and patients with known active Crohn's disease (CD 1-6). Patients with GVHD are coded by GVHD 1-9. At the bottom line of each group the mean signal with its s.d. is calculated.
Klein et al. 14 evaluated high-resolution ultrasound with color Doppler imaging in 12 patients with suspected GVHD. All patients showed thickened bowel wall segments. In 4 of 12 patients, increased arterial blood flow in the bowel wall was revealed while in another four patients ischemic bowel wall lesions with high-resistance flow pattern in the superior mesenteric artery were found, which correlated with a poor prognosis. A study by Go¨rg et al. evaluates typical findings detected by high-resolution ultrasound in seven patients with GVHD. 15 Dilatation of the bowel was assessed in all patients (colon 6/7, small bowel 5/7) leading to detection of a thickened bowel wall in 6/7, wall stratification in 5/7, hyperperistalsis in 6/7 and free abdominal fluid in 5/7 patients. Unfortunately, these features are not at all specific.
As in the above mentioned papers, the results of our study show the nonspecific signs of GVHD such as bowel dilatation with excessive fluid within the bowel lumen, bowel wall thickening in the ileocecal region and hyperperistalsis and abnormal increased contrast uptake of the bowel wall. Additionally, we found the penetration of microbubbles detected by ultrasound to be a new feature in all patients with GVHD examined, which was not present in healthy volunteers or patients with chronic bowel inflammation.
We assume that the damaged gut mucosal barrier, which is more permeable in patients with GVHD, 16 is responsible for the permeation of microbubbles through the mucosa into the bowel lumen. Additionally, our observation may reflect the apoptotic damage of epithelial cells resulting in loss of crypts 17, 18 which is a typical feature of acute GVHD. Nevertheless, it has to be taken into consideration that calcineurin inhibitors and steroids, agents frequently used in GVHD treatment, can lead to endothelial lesions and pericapillary hemorrhage 19 or thrombotic microangiopathy, thus facilitating the penetration of microbubbles. 20, 21 The generally higher baseline signal in patients with GVHD is another interesting observation. We believe that the increased local vascularization is the reason for this phenomenon in the surrounding mesenteric fat, as well as within the bowel wall. The higher intraluminal baseline signal in our patients was based on motion artifacts of the intraluminal fluid, which contains solid structures composed of scaled off mucosal material. Unlike color-coded Doppler sonography and power Doppler imaging, our advanced ultrasound technique allows us to clearly visualize the microbubbles within the fluid-filled bowel lumen and to measure the signal based on the microbubbles quantitatively.
Conclusion
This study is a feasibility study with a small number of patients which describes the visualization of microbubbles penetrating the bowel wall in patients with GVHD as a new diagnostic feature for the first time. Further studies comparing patients prior to onset and at the time of onset of GVHD as well patients with and without GVHD after PBSCT are necessary to distinguish regimen-related mucosal damage by irradiation or high-dose chemotherapy from GVHD. In addition, it is necessary to evaluate this feature in patients after PBSCT suffering from CMV infection and bacterial enteritis for further differential diagnosis. Finally, an evaluation of this technique as a potential early indicator of intestinal GVHD is necessary.
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